FDA 510(k) vs. PMA: How Medical Devices Are Approved
Published March 2026 · 8 min read
Medically reviewed by licensed healthcare professionals · Legally reviewed by mass tort litigation specialists · Last updated:
In medical device litigation, you will often hear about the FDA's "510(k) clearance" process. Most patients assume that any device used in surgery has been rigorously tested and "FDA Approved," but the reality is more complex. Understanding the difference between the 510(k) pathway and the more stringent Premarket Approval (PMA) process is key to understanding how devices like surgical breast mesh can come to market and later be found to have problems.
The Two Main Paths to Market
The FDA has two primary tracks for clearing or approving medical devices:
- Premarket Approval (PMA): This is the most rigorous path. It is required for Class III devices—those that are high-risk, life-supporting, or life-sustaining. The PMA process requires manufacturers to submit extensive scientific evidence, including data from clinical trials, to prove that the device is safe and effective for its intended use. It is a true "approval" process.
- Premarket Notification 510(k): This is a far more common and less stringent pathway. It is used for most Class II (moderate-risk) and some Class I (low-risk) devices. A 510(k) does not require clinical trials. Instead, a manufacturer must only show that their new device is "substantially equivalent" to a device that is already legally on the market (a "predicate device"). This is a "clearance" process, not an "approval."
The 510(k) "Substantial Equivalence" Loophole
The 510(k) process was intended to be a shortcut for simple, low-risk devices like tongue depressors or updated versions of existing devices with minor modifications. However, over time, it became the default pathway for many complex implantable devices, including most surgical meshes.
The problem lies in the concept of "substantial equivalence." A new device can be cleared by claiming it is equivalent to a predicate device that was on the market before 1976 (when the law was passed), or to a device that was itself cleared through the 510(k) process. This can create "chains" of equivalence, where a new device is cleared based on a predicate, which was based on an even older predicate, stretching back for decades. At no point in this chain is the manufacturer required to produce new clinical trial data proving the final device is safe and effective for its modern use.
Surgical breast mesh products like GalaFLEX were cleared through the 510(k) pathway. They were often deemed substantially equivalent to hernia mesh products, even though the biological environment and mechanical stresses in the breast are vastly different from those in the abdominal wall.
Why This Matters for Patient Safety and Litigation
The 510(k) process has been heavily criticized by patient safety advocates and government watchdogs for years. The key issues are:
- Lack of Clinical Data: A device can be implanted in thousands of patients without the manufacturer ever having conducted a single robust clinical trial to study its long-term performance for that specific use.
- Outdated Predicates: A new device can be cleared based on a predicate that was later recalled for safety reasons.
- "Off-Label" Use: A mesh might be cleared for a general use like "soft tissue support," but then heavily marketed to surgeons for a specific, more demanding use like breast reconstruction, for which it was never clinically tested.
In a lawsuit against a mesh manufacturer, the fact that the device was cleared via 510(k) is a central piece of evidence. Plaintiff's attorneys argue that the manufacturer took advantage of this regulatory loophole to rush a product to market without adequate testing, and that "FDA Cleared" is not the same as "Proven Safe." They will argue that the manufacturer had a duty to perform proper testing for the device's intended use, regardless of what the FDA's minimum requirements were.
Legal Preemption: A Hurdle for PMA Devices
Ironically, it can be *harder* for a patient to sue over a device that went through the rigorous PMA process. A legal doctrine called "preemption" can sometimes protect manufacturers of PMA-approved devices from state-law personal injury lawsuits, under the theory that they met the FDA's highest standards and state courts should not be allowed to second-guess that.
However, this preemption defense generally does not apply to devices cleared through the 510(k) pathway. Courts have consistently ruled that because 510(k) is a lower standard, it does not preempt patients' rights to bring lawsuits for their injuries. This is a critical legal distinction that allows litigation over most surgical mesh products to proceed.
What This Means for You as a Patient
When discussing a medical implant with your surgeon, it is reasonable to ask about its regulatory history. "Was this device FDA approved through PMA, or was it cleared through 510(k)?", "What clinical data is there to support its use for this specific purpose?".
If you have been injured by a device, don't assume that "FDA Cleared" means you don't have a case. The regulatory pathway is a key part of the legal analysis, and the fact that a device like GalaFLEX avoided rigorous clinical testing is often a central part of the argument that the manufacturer failed to ensure it was safe.